VERX Stock Recent News

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” Negulescu shares the award with Michae.

Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.

The Investment Committee give you their top stocks to watch in this volatile markets.

Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers

SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, announced that the Elasticsearch vector database is now a natively supported information retrieval engine for Google Cloud's Vertex AI platform. “By integrating Elasticsearch as a native grounding engine in Google Cloud's Vertex AI platform, our joint customers can seamlessly build RAG applications in a single workflow,” said Shay Banon, founder and chief technology officer at Elastic. “This solution enables faster dep.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.75%). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2025 Earnings Call.” The conference call will be webcast live and a link to the webcast can be a.

Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunopro.

The Investment Committee give you their stop stocks to watch for the second half.